Scholars Central

Conference abstractPublished 11 Aug 2015

Developing VLP (Virus like particle) based nano-particulate HPV (Human papillomavirus) vaccine for cervical cancer

Authors: Mohammad Nasir Uddin

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Cervical cancer is the second most cause of cancer related death among women all over the world. Two HPV type-specific prophylactic vaccines are currently being used world-wide. However, the cost of the vaccine itself, the expensive storage system, need for an expert to administer the vaccines tremendously inhibits the global use of the vaccines. Moreover recent controversy over the side effects of both vaccines also calls for a demand to develop an alternative vaccine which will be able to address all the issues. The goal of this project is to develop a nano particulate VLP based HPV vaccine that will be cost effective, highly potent and can be used in resource poor countries. The VLP containing particulate vaccines were prepared in a simple one step spray drying process using a Eudragit polymer. The size, shape and surface morphology of the particles were determined by scanning electron microscopy (SEM). Within the particle, the presence of VLP was detected using SDS-PAGE analysis and quantified using Western blot. The functionality of the vaccine was tested in an in vivo animal model using Swiss Webster mice. The antibody obtained from serum was analyzed by ELISA. The presence of intact VLPs was confirmed by TEM images. The animal study showed the significantly high titer. Based on these primary results we envision that the current formulation would offer mucosal and systemic protection by taking the advantages of particulate form of vaccines at multiple anatomic sites that are vulnerable to HPV infection and associated disease progression.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDrug Designing: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Mohammad Nasir Uddin”